%0期刊文章%@ 1438- 8871% I JMIR出版物%V 19卡塔尔世界杯8强波胆分析% N 1% P e10% T IntelliCare:Mohr,David C . A Tomasino,Kathryn Noth Lattie,Emily G . A Palac,Hannah L . A Kwasny,Mary J . A Weingardt,Kenneth R . A Karr,Chris J . A Kaiser,Susan M . A Rossom,Rebecca C . A Bardsley,Leland R . A Caccamo,Lauren Stiles-Shields,Colleen A Schueller，西北大学预防医学系行为干预技术中心(CBITs)， 750 N lakeshoddrive, 10楼，芝加哥，IL, 60611，美国，1 312 503 1403,d-mohr@northwestern.edu %K移动健康%K电子健康%K移动健康%K抑郁%K焦虑%D 2017 %7 05.01.2017 %9原始论文%J J医学互联网Res %G英语%X背景:数字精神健康工具倾向于使用基于在数字健康之外开发和验证的治疗取向的心理教育策略。这些功能与今天人们使用手机和手机应用程序的简单而频繁的方式并不匹配。为了应对这些挑战，我们开发了一套名为IntelliCare的抑郁和焦虑应用程序，每个应用程序都有一个明确的目标和互动风格。IntelliCare应用程序优先考虑交互技能培训，而不是教育，并专为频繁但短时间的交互而设计。目的:本研究的总体目标是试点教练辅助版IntelliCare，并评估其在减轻抑郁和焦虑症状方面的使用和疗效。方法:通过医疗保健系统、网络和社区广告以及临床研究注册招募的参与者，如果他们有抑郁或焦虑的症状加重，就被纳入这项单臂试验。参与者可以使用谷歌Play的14个IntelliCare应用程序，并接受了8周的IntelliCare使用指导。培训包括最初的电话和每周2个或更多的短信，在8周内，一些参与者还会收到额外的简短电话。 Primary outcomes included the Patient Health Questionnaire-9 (PHQ-9) for depression and the Generalized Anxiety Disorder-7 (GAD-7) for anxiety. Participants were compensated up to US $90 for completing all assessments; compensation was not for app use or treatment engagement. Results: Of the 99 participants who initiated treatment, 90.1% (90/99) completed 8 weeks. Participants showed substantial reductions in the PHQ-9 and GAD-7 (P<.001). Participants used the apps an average of 195.4 (SD 141) times over the 8 weeks. The average length of use was 1.1 (SD 2.1) minutes, and 95% of participants downloaded 5 or more of the IntelliCare apps. Conclusions: This study supports the IntelliCare framework of providing a suite of skills-focused apps that can be used frequently and briefly to reduce symptoms of depression and anxiety. The IntelliCare system is elemental, allowing individual apps to be used or not used based on their effectiveness and utility, and it is eclectic, viewing treatment strategies as elements that can be applied as needed rather than adhering to a singular, overarching, theoretical model. Trial Registration: Clinicaltrials.gov NCT02176226; http://clinicaltrials.gov/ct2/show/NCT02176226 (Archived by WebCite at http://www.webcitation/6mQZuBGk1) %M 28057609 %R 10.2196/jmir.6645 %U //www.mybigtv.com/2017/1/e10/ %U https://doi.org/10.2196/jmir.6645 %U http://www.ncbi.nlm.nih.gov/pubmed/28057609